Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00 at Lake Street Capital

Checkpoint Therapeutics (NASDAQ:CKPT) had its price target lifted by Lake Street Capital from $4.00 to $7.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday.

Checkpoint Therapeutics Trading Down 7.6 %

Shares of CKPT stock opened at $3.39 on Monday. The company has a market cap of $165.53 million, a P/E ratio of -1.84 and a beta of 1.34. The firm has a fifty day moving average price of $3.50 and a 200 day moving average price of $2.67. Checkpoint Therapeutics has a 12 month low of $1.36 and a 12 month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, equities analysts forecast that Checkpoint Therapeutics will post -0.91 EPS for the current year.

Institutional Trading of Checkpoint Therapeutics

A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of Checkpoint Therapeutics in the third quarter valued at about $30,000. XTX Topco Ltd acquired a new position in Checkpoint Therapeutics in the 2nd quarter valued at about $34,000. Gladstone Institutional Advisory LLC raised its stake in Checkpoint Therapeutics by 141.4% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 20,500 shares during the last quarter. Magnus Financial Group LLC lifted its position in Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after acquiring an additional 4,000 shares during the period. Finally, Choreo LLC grew its stake in shares of Checkpoint Therapeutics by 12.2% in the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares during the last quarter. Institutional investors and hedge funds own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.